



# Global Polio Eradication Initiative Strategic Plan 2004–2008



WHO



Partners in the Global Polio Eradication Initiative

WHO Library Cataloguing-in-Publication Data

Global Polio Eradication Initiative.

Global Polio Eradication Initiative : strategic plan 2004-2008.

1. Poliomyelitis – prevention and control
2. Poliovirus vaccine
- Oral – supply and distribution
3. Immunization programs – organization and administration
4. Strategic planning I. Title.

ISBN 92 4 159117 X

(NLM classification: WC 556)

© World Health Organization 2003

All rights reserved. Publications of the World Health Organization can be obtained from Marketing and Dissemination, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel: +41 22 791 2476; fax: +41 22 791 4857; email: [bookorders@who.int](mailto:bookorders@who.int)). Requests for permission to reproduce or translate WHO publications – whether for sale or for noncommercial distribution – should be addressed to Publications, at the above address (fax: +41 22 791 4806; email: [permissions@who.int](mailto:permissions@who.int)).

The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

The World Health Organization does not warrant that the information contained in this publication is complete and correct and shall not be liable for any damages incurred as a result of its use.

Printed in Switzerland

# **Global Polio Eradication Initiative Strategic Plan**

**2004–2008**

# Contents

Abbreviations and acronyms	3
<b>1</b> Executive summary	4
<b>2</b> Background	6
<b>3</b> Goal	8
<b>4</b> Objectives and milestones	9
4.1 Objective 1: Interrupt poliovirus transmission	9
4.2 Objective 2: Achieve certification of global polio eradication	17
4.3 Objective 3: Develop products for the Global OPV Cessation Phase	22
4.4 Objective 4: Mainstream the Global Polio Eradication Initiative	27
<b>5</b> Cross-cutting challenges	32
5.1 Political commitment and engagement	32
5.2 External financing	32
5.3 High-quality polio vaccines	33
5.4 Conflict-affected countries and areas	33
5.5 Public information and social mobilization	33
5.6 Biocontainment	34
<b>6</b> Roles of partner agencies	35
6.1 Governments	35
6.2 Spearheading partners	35
6.3 Donor and technical partners	36
6.4 International humanitarian organizations and NGOs	37
6.5 Vaccine manufacturers	38
<b>7</b> 2009 & Beyond – the Global OPV Cessation Phase	39

# A b b r e v i a t i o n s   a n d

## A c r o n y m s

<b>AFP</b>	acute flaccid paralysis
<b>AFR</b>	WHO African Region
<b>AMR</b>	WHO Region of the Americas
<b>ARVs</b>	anti-retroviral drugs
<b>CCM</b>	Country coordination mechanism
<b>CDC</b>	US Centers for Disease Control and Prevention (USA)
<b>CIDA</b>	Canadian International Development Agency
<b>cVDPV</b>	circulating vaccine-derived poliovirus
<b>DFID</b>	Department for International Development (United Kingdom)
<b>EC</b>	European Commission
<b>EMR</b>	WHO Eastern Mediterranean Region
<b>GAVI</b>	Global Alliance for Vaccines and Immunization
<b>GCC</b>	Global Commission for the Certification of the Eradication of Poliomyelitis
<b>GOARN</b>	Global Outbreak Alert and Reponse Network
<b>kfW</b>	Kreditanstalt für Wiederaufbau (Germany)
<b>ICCs</b>	interagency coordinating committees
<b>IDS</b>	integrated disease surveillance
<b>iNIDs</b>	intensified national immunization days
<b>IPV</b>	inactivated poliovirus vaccine
<b>iSNIDs</b>	intensified subnational immunization days
<b>ITD</b>	intratypic differentiation
<b>ITN</b>	insecticide treated net
<b>JICA</b>	Japan International Cooperation Agency
<b>MDGs</b>	millennium development goals
<b>mOPV</b>	monovalent oral polio vaccine
<b>NCCs</b>	national certification committees
<b>NGOs</b>	nongovernmental organizations
<b>NIDs</b>	national immunization days
<b>OPV</b>	oral polio vaccine
<b>RCCs</b>	regional certification commissions
<b>RED</b>	Reach Every District
<b>SIAs</b>	supplementary immunization activities (e.g. NIDs, SNIDs, mop-ups)
<b>SEAR</b>	WHO South-East Asia Region
<b>SNIDs</b>	subnational immunization days
<b>TAGs</b>	technical advisory groups
<b>TCG</b>	global Technical Consultative Group for Poliomyelitis Eradication
<b>UN</b>	United Nations
<b>UNF</b>	United Nations Foundation
<b>UNICEF</b>	United Nations Children's Fund
<b>USAID</b>	United States Agency for International Development
<b>VAPP</b>	vaccine-associated paralytic poliomyelitis
<b>VDPVs</b>	vaccine-derived polioviruses
<b>VPDs</b>	vaccine-preventable diseases
<b>WHA</b>	World Health Assembly
<b>WHO</b>	World Health Organization
<b>WPR</b>	WHO Western Pacific Region

# 1 Executive Summary

**B**y end-2003, poliomyelitis had been eliminated from all but 6 countries<sup>1</sup> in the world as a result of the Global Polio Eradication Initiative, the largest international public health effort to date. Nearly 5 million children are walking who would otherwise have been paralyzed by polio and 1.25 million childhood deaths have been averted by distributing Vitamin A during the polio immunization campaigns.

Once polio has been eradicated, the world will reap substantial financial, as well as humanitarian, dividends due to foregone polio treatment and rehabilitation costs. Depending on national decisions on the future use of polio vaccines, these savings could exceed US\$ 1 billion per year.

The Global Polio Eradication Initiative Strategic Plan 2004-2008<sup>2</sup> outlines activities required to interrupt poliovirus transmission (2004-2005), achieve global certification and mainstream the Global Polio Eradication Initiative (2006-2008), and prepares for the Global OPV Cessation Phase (2009 & beyond). This Plan reflects the major tactical revisions that were introduced in 2003 to interrupt the final chains of polio transmission, the revised timeframe for certification of eradication, and the decision to stop immunization with oral polio vaccine (OPV) globally as soon as possible after global certification.

Of the 4 objectives outlined in the Plan, the over-riding objective is the rapid interruption of polio transmission in the 6 remaining endemic countries. Eliminating these reservoirs during 2004-2005 is now an urgent international public health issue because the cessation of mass immunization campaigns in most polio-free countries has left the world increasingly vulnerable to importations of this disease. Objective 1 of the Plan details the supplementary immunization, routine immunization, and surveillance activities needed to finish the job of eradication and protect the investment made in polio-free areas. Particular

attention is given to 'intensifying' supplementary immunization activities to improve quality and reach every child. The Plan highlights the 3 countries linked to over 95% of cases in 2003: Nigeria, India and Pakistan. It recognizes, however, that with the reduction in polio transmission in India and Pakistan in late 2003, the risks to global eradication are increasingly concentrated in Nigeria. The postponement of eradication activities in key areas of that country in 2003 led to a marked increase in the number of polio-paralyzed Nigerian children and the re-infection of at least 5 neighbouring countries. The narrow window of opportunity that now exists to eradicate polio can only be exploited if the leaders of the endemic areas ensure that every child is immunized during intensified supplementary immunization activities in 2004 (SIAs).

Objectives 2 and 3 of the Plan outline activities for certifying the world polio-free and preparing for the Global OPV Cessation Phase that will follow. With the certification process and criteria having been validated in three WHO regions, Objective 2 focuses on improving surveillance quality (especially in the 19 countries yet to achieve certification-standard), reversing declines in surveillance sensitivity in the regions that have been certified, and completing Phase II of the *Global Action Plan for the Laboratory Containment of Wild Polioviruses*. Objective 3 outlines the implications of the 2003 decision to stop OPV after global certification. Although trivalent OPV will continue to be the vaccine of choice for routine immunization through 2008, the plan outlines the work required to develop the specific products needed to facilitate the safe cessation of OPV. These products include: a 3<sup>rd</sup> edition of the Global Action Plan for the Laboratory Containment of Wild Polioviruses (specifying the longterm requirements for wild poliovirus, vaccine-derived polioviruses and Sabin-strains), monovalent OPV (mOPV) stockpiles, IPV produced from Sabin strains (S-IPV), and appropriate IPV-containing combination vaccines. The plan also discusses the

<sup>1</sup> Countries with ongoing indigenous wild polioviruses in 2003, in order of intensity of transmission, were: Nigeria, India, Pakistan, Niger, Afghanistan and Egypt.

<sup>2</sup> This plan replaces and updates the Global Polio Eradication Strategic Plan 2001-2005. WHO Document No. WHO/Polio/00.05.



development of mechanisms to ensure that countries which desire or need these products have access to them by 2008.

The fourth and final objective of the plan addresses the work required to integrate and/or transition the substantial human resources, physical infrastructure and institutional arrangements that were established for polio eradication into other disease control, surveillance and response programmes. This objective also details the programme of work to 'mainstream' those polio eradication activities that must be continued indefinitely (i.e. surveillance, stockpiles, containment) into existing national, WHO and UNICEF structures and mechanisms for managing other serious pathogens which are subject to high biosafety levels.

The greatest risks to achieving the annual milestones of this plan are ongoing wild

poliovirus transmission in any of the 6 remaining endemic countries and an increased frequency of polio outbreaks due to circulating vaccine-derived polioviruses (cVDPVs). Implementing the full activities outlined in the Plan requires continued technical support from a strong polio eradication partnership, financing for the shortfall of US\$ 150 million to interrupt poliovirus transmission, and identification of funding for the US\$ 380 million budget to achieve global certification and mainstream the Global Polio Eradication Initiative.

The Global Polio Eradication Initiative Estimated External Financial Resource Requirements 2004–2008 outlines the resources required to implement the Global Polio Eradication Initiative Strategic Plan 2004–2008<sup>3</sup> and the financial implications of the major risks to the annual milestones of the Plan. □

<sup>3</sup> WHO/UNICEF Global Polio Eradication Initiative Estimated External Financial Resource Requirements 2004–2008.

## 2 Background

In 1988 the World Health Assembly (WHA), the annual meeting of the ministers of health of all Member States of the World Health Organization, voted to launch a global initiative to eradicate polio. As a result of the Global Polio Eradication Initiative, the largest international public health effort to date, by late-2003 polio had been eliminated from all but 6 countries and fewer than 1000 children had been paralysed by the disease that year. More notably, nearly five million children were walking who would otherwise have been paralysed by polio and 1.25 million childhood deaths had been averted by distributing vitamin A during the polio immunization campaigns.

The international decision to pursue eradication of this devastating disease was based on sound evidence from the WHO Region of the Americas (AMR) as to the technical feasibility of such a goal, and on the political and societal support best exemplified by the commitment of

the service organization Rotary International to raise financial resources and advocate for polio eradication. In the 15 years since the decision to eradicate polio, an extensive network of national governments, international agencies, private corporations, foundations, bilateral donors, humanitarian organizations, nongovernmental organizations (NGOs) and development banks have formed a “global polio partnership”, spearheaded by the World Health Organization (WHO), Rotary International, the US Centers for Disease Control and Prevention (CDC) and the United Nations Children’s Fund (UNICEF).

Between 1988 and the mid-1990s, there was a limited reduction in the number of endemic countries as the partnership was developed, broader political commitment secured and further evidence of the operational feasibility of the AMR strategies established, particularly in the Western Pacific Region (WPR). From the mid-1990s, it was possible to rapidly scale-up eradication

**Figure 1:** Key targets to *interrupt poliovirus transmission* (2004-2005), achieve *global certification and mainstream the Global Polio Eradication Initiative* (2006-2008), and during the *Global OPV Cessation Phase* (2009 & beyond)



预览已结束，完整报告链接和二维码如下：

[https://www.yunbaogao.cn/report/index/report?reportId=5\\_30140](https://www.yunbaogao.cn/report/index/report?reportId=5_30140)

